Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, Infection, Coronavirus, Respiratory Tract Infections, SARS-CoV2 Infection, Viral Infection
Conditions
Keywords
covid-19, supportive care, Immuno-modulator, antiviral, symptoms relieve
Brief summary
This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.
Detailed description
This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection. A total of 80 subjects will be randomized 2:1 in this study. 50 patients will be assigned to receive daily oral doses of 4,5 g of Viusid every 12 hours and 10 ml of Asbrip every 12 hours and standard care with antivirals or not. Other 30 patients will be assigned to receive only standard care. Treatment duration: 21 days Objective of the study: to increase the effectiveness of therapy for patients with Covid-19 using food supplements Viusid and Asbrip. Research objectives: 1. To assess the clinical symptoms of Covid-19 in patients on the background of combination therapy with the inclusion of food supplements Viusid + Asbrip. 2. To investigate the dynamics of indicators of laboratory diagnostics against the background of complex therapy with the inclusion of food additives Viusid + Asbrip in the complex treatment of Covid -19. 3. To study the dynamics of indicators of instrumental methods of treatment. 4. To develop an algorithm for the management of patients with coronavirus infection in order to increase the effectiveness of therapy and rehabilitation of patients with this pathology.
Interventions
DIETARY_SUPPLEMENTViusid and Asbrip
Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
DRUGCOVID-19 Standard Therapy
Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Sponsors
Catalysis SL
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
The eligibility criteria for inclusion in the study were as follows: * Male and female hospitalized patients who have signed an informed consent. * Aged between 18-85 years old. * RT-PCR confirmed COVID-19. * Fever (over 37.2 Celsius degrees). * CT scan percentage area of lung involvement with ground-glass opacities \< 50 %. * Respiratory rate \< 20-30 /min * SpO2 ≥ 95%. The
Exclusion criteria
were as follows: * Oxygen support (ventilation and non-invasive) * Uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings. * Any known intolerability to any of the study regimens' components. * Patient's family or official relations with a member of staff of the clinical site. * Patient's failure to assess his/her physical and/or emotional condition. * Patient's failure to comply with the study requirements. * Patient's refusal to participate in the study. * Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean duration of hospitalization. | 21 days | Media of time in days to discharge in each group. Discharge is considered once the patient complete the following conditions: * Normal body temperature for 2 days (36.1 - 37.2 degrees Celsius will be considered as normal body temperature). * Normal appetite for 4 days. * Normal Complete Blood Count (CBC): Following values will be considered as normal values in CBC: Red blood cell count: Male: 4.35-5.65 million cells/mcL; Female: 3.92-5.13 million cells/mcL. Hemoglobin: Male: 13.2-16.6 grams/dL; Female: 11.6-15 grams/dL. Hematocrit: Male: 38.3-48.6 percent; Female: 35.5-44.9 percent. White blood cell count: 3,400 to 9,600 cells/mcL. Platelet count: Male: 135-317 billion/L; Female: 157-371 billion/L. * No requirement in oxygen support. * Decrease in or normal CRP: 0.8-1.0 mg/dL (or 8-10 mg/L) or lower will be considered as normal values. * Any decrease in IL-6 level lower than doubled normal value: between 0 and 43.5 pg/ml will be considered as normal values. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean levels of IL-6 concentration | 21 days | Mean of IL-6 concentration measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. IL-6 level lower than doubled normal value: between 0 and 43.5 pg/ml will be considered as normal values. Levels of IL-6 will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/). |
| Peripheral blood c-reactive protein concentration | 21 days | Peripheral blood c-reactive protein concentration measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. \- 0.8-1.0 mg/dL (or 8-10 mg/L) or lower will be considered as normal values. Levels of CRP will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/). |
| Mean levels of D-Dimer concentration | 21 days | Mean of D-dimer measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. D-Dimer level under 250 ng/mL, or under 0.4 μ/mL will be considered as normal value. Levels of D-Dimer will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/). |
| Mean levels of Ferritin concentration | 21 days | Mean of D-dimer measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. In adult Males between 12 to 300 ng/mL; in adult Females between 12 to 150 ng/mL will be considered as normal values. Levels of Ferritin will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/). |
Countries
Kazakhstan
Outcome results
None listed